Home > E. Pathology by systems > Nervous system > Central nervous system > Brain > glioblastoma
glioblastoma
Saturday 6 November 2004
Loss of heterozygosity (Allelotyping) (#12875726#)
| 3q25.2-26.2 LOH | |||
| 4q31.1-31.2 LOH | |||
| 4q35 LOH | |||
| 6q21-23.3 LOH | |||
| 6q27 LOH | |||
| 9p21-23 LOH | 31% | CDKN2A (p16) | CDKN2B (p15) |
| 9q LOH | |||
| 10p12.2-14 LOH | |||
| 10q LOH | 69% | ||
| 10q21.3 LOH | |||
| 10q23 LOH | 24%-69% | PTEN | |
| 10q25.3-q26.1 LOH | DMBT1 | ||
| 11p12-13 LOH | |||
| 13q12.1-14.1 LOH | |||
| 13q14.3-31 LOH | RB | ||
| 14q11.1-13 LOH | |||
| 14q13-31 LOH | |||
| 14q32.1 LOH | |||
| Chr.15 LOH | |||
| 17p11.2-12 LOH | |||
| 17p13 LOH | 31% | TP53 | |
| 19q LOH | |||
| 22q13.3 LOH |
Gene inactivations
| TP53 | 31% | 17p13 |
| CDKN2A (p16) | 31% | 9p21 |
| PTEN | 24% | 10q23 |
Glioblastomas frequently carry mutations in the PTEN tumor suppressor gene on 10q23.3 (24%).
Gene overexpressions
EGFR amplification (34%)
Amplified regions and gene copy increases (chromosome gains, genic amplifications)
Chr.7 (radiation resistance) (#16130123#) Chr.1 Chr.4 Chr.11 Chr.12
Molecular pathways
genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3’-kinase/protein kinase B (Akt) signal transduction pathway in glioblastoma (#14655756#)
Variants
primary glioblastoma (de novo) prevailed (95%) secondary glioblastoma
References
Ohgaki H. Genetic pathways to glioblastomas. Neuropathology. 2005 Mar;25(1):1-7. PMID: #15822813#
References
Gilbertson RJ, Rich JN. Making a tumour’s bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer. 2007 Oct;7(10):733-6. PMID: #17882276#
Knobbe CB, Reifenberger G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3’-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol. 2003 Oct;13(4):507-18. PMID: #14655756#
